ERIBULIN MESYLATE

N/A

Manufactured by BSP Pharmaceuticals SpA

6,741 FDA adverse event reports analyzed

Last updated: 2026-04-15

About ERIBULIN MESYLATE

ERIBULIN MESYLATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by BSP Pharmaceuticals SpA. The most commonly reported adverse reactions for ERIBULIN MESYLATE include NEUTROPENIA, MALIGNANT NEOPLASM PROGRESSION, FEBRILE NEUTROPENIA, MYELOSUPPRESSION, PYREXIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ERIBULIN MESYLATE.

Top Adverse Reactions

NEUTROPENIA527 reports
MALIGNANT NEOPLASM PROGRESSION377 reports
FEBRILE NEUTROPENIA330 reports
MYELOSUPPRESSION291 reports
PYREXIA212 reports
NEUROPATHY PERIPHERAL211 reports
LEUKOPENIA201 reports
INTERSTITIAL LUNG DISEASE181 reports
WHITE BLOOD CELL COUNT DECREASED173 reports
NEUTROPHIL COUNT DECREASED169 reports
NAUSEA155 reports
FATIGUE153 reports
ASTHENIA134 reports
PNEUMONIA120 reports
DECREASED APPETITE117 reports
DIARRHOEA110 reports
VOMITING105 reports
DYSPNOEA104 reports
ALOPECIA103 reports
ANAEMIA102 reports
STOMATITIS102 reports
THROMBOCYTOPENIA99 reports
MALAISE90 reports
DEATH78 reports
SEPSIS77 reports
HEADACHE74 reports
DISEASE PROGRESSION70 reports
PLATELET COUNT DECREASED67 reports
OFF LABEL USE63 reports
PLEURAL EFFUSION61 reports
MUCOSAL INFLAMMATION58 reports
COUGH56 reports
OSTEONECROSIS OF JAW55 reports
ABDOMINAL PAIN49 reports
CONSTIPATION49 reports
PANCYTOPENIA49 reports
CARDIAC FAILURE47 reports
PAIN44 reports
BREAST CANCER42 reports
HYPOAESTHESIA41 reports
METASTASES TO LIVER40 reports
URINARY TRACT INFECTION40 reports
BACK PAIN39 reports
DRUG INEFFECTIVE39 reports
GENERAL PHYSICAL HEALTH DETERIORATION39 reports
NEOPLASM PROGRESSION39 reports
DIZZINESS38 reports
HEPATIC FUNCTION ABNORMAL38 reports
PULMONARY EMBOLISM38 reports
RASH38 reports
BREAST CANCER METASTATIC37 reports
PAIN IN EXTREMITY36 reports
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME35 reports
LYMPHOPENIA34 reports
PNEUMOTHORAX34 reports
WEIGHT DECREASED34 reports
ASPARTATE AMINOTRANSFERASE INCREASED32 reports
METASTASES TO CENTRAL NERVOUS SYSTEM32 reports
ALANINE AMINOTRANSFERASE INCREASED31 reports
ASCITES31 reports
METASTASES TO BONE31 reports
TREMOR29 reports
HAEMOGLOBIN DECREASED28 reports
HYPOKALAEMIA28 reports
DYSPHONIA26 reports
BLOOD BILIRUBIN INCREASED25 reports
CHILLS25 reports
ARTHRALGIA24 reports
BLOOD CREATININE INCREASED24 reports
DEHYDRATION24 reports
CELLULITIS23 reports
COLITIS23 reports
DYSPEPSIA23 reports
MUSCULAR WEAKNESS23 reports
DRUG INTOLERANCE22 reports
HEPATIC FAILURE22 reports
ELECTROCARDIOGRAM QT PROLONGED21 reports
FALL21 reports
HEPATIC ENZYME INCREASED21 reports
OEDEMA PERIPHERAL21 reports
PALPITATIONS21 reports
RENAL FAILURE21 reports
SEPTIC SHOCK21 reports
ACUTE KIDNEY INJURY20 reports
CHEST PAIN20 reports
GAIT DISTURBANCE20 reports
HYPERTENSION20 reports
INFECTION20 reports
PERIPHERAL SENSORY NEUROPATHY20 reports
PROTEIN TOTAL INCREASED20 reports
HYPERGLYCAEMIA19 reports
HYPOTENSION19 reports
PNEUMONITIS19 reports
RASH PRURITIC19 reports
HEPATIC CIRRHOSIS18 reports
IMMUNOSUPPRESSION18 reports
MOUTH ULCERATION18 reports
OEDEMA18 reports
RESPIRATORY FAILURE18 reports
TACHYCARDIA18 reports

Report Outcomes

Out of 3,659 classified reports for ERIBULIN MESYLATE:

Serious 92.6%Non-Serious 7.4%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female3,328 (94.3%)
Male196 (5.6%)
Unknown7 (0.2%)

Reports by Age

Age 58103 reports
Age 5798 reports
Age 5596 reports
Age 4994 reports
Age 5493 reports
Age 5990 reports
Age 6090 reports
Age 6188 reports
Age 5287 reports
Age 5180 reports
Age 6479 reports
Age 6577 reports
Age 6777 reports
Age 7077 reports
Age 6675 reports
Age 5374 reports
Age 5072 reports
Age 4766 reports
Age 5666 reports
Age 6263 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with ERIBULIN MESYLATE?

This profile reflects 6,741 FDA FAERS reports that mention ERIBULIN MESYLATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for ERIBULIN MESYLATE?

Frequently reported terms in FAERS include NEUTROPENIA, MALIGNANT NEOPLASM PROGRESSION, FEBRILE NEUTROPENIA, MYELOSUPPRESSION, PYREXIA, NEUROPATHY PERIPHERAL. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures ERIBULIN MESYLATE?

Labeling and FAERS entries often list BSP Pharmaceuticals SpA in connection with ERIBULIN MESYLATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.